REFERENCES
1. Torrisi F, Alberghina C, D’Aprile S, et al. The hallmarks of glioblastoma: heterogeneity, intercellular crosstalk and molecular signature of invasiveness and progression. Biomedicines. 2022;10:806.
2. Lauko A, Lo A, Ahluwalia MS, Lathia JD. Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. Semin Cancer Biol. 2022;82:162-75.
3. Becker AP, Sells BE, Haque SJ, Chakravarti A. Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers. 2021;13:761.
4. Hutóczki G, Virga J, Birkó Z, Klekner A. Novel concepts of glioblastoma therapy concerning its heterogeneity. Int J Mol Sci. 2021;22:10005.
5. Oliver L, Lalier L, Salaud C, Heymann D, Cartron PF, Vallette FM. Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist. 2020;3:287-301.
6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
7. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70:299-312.
9. Arora A, Somasundaram K. Glioblastoma vs temozolomide: can the red queen race be won? Cancer Biol Ther. 2019;20:1083-90.
10. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5:102-14.
11. Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876:188616.
12. Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4:17-43.
13. Choo M, Mai VH, Kim HS, et al. Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. Acta Pharmacol Sin. 2023;44:670-9.
14. Kopecka J, Riganti C. Overcoming drug resistance in glioblastoma: new options in sight? Cancer Drug Resist. 2021;4:512-6.
15. Bao Z, Wang Y, Wang Q, et al. Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. Front Med. 2021;15:551-61.
16. Virtuoso A, Giovannoni R, De Luca C, et al. The glioblastoma microenvironment: morphology, metabolism, and molecular signature of glial dynamics to discover metabolic rewiring sequence. Int J Mol Sci. 2021;22:3301.
17. Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. The interplay between glioblastoma and its microenvironment. Cells. 2021;10:2257.
18. DeCordova S, Shastri A, Tsolaki AG, et al. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. Front Immunol. 2020;11:1402.
19. Eisenbarth D, Wang YA. Insights into the co-evolution of glioblastoma and associated macrophages. J Cancer Metastasis Treat. 2023;9:14.
20. Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives. Cancers. 2022;14:443.
21. Marino S, Menna G, Di Bonaventura R, et al. The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment-a systematic review. Cancers. 2023;15:1879.
22. Towner RA, Zalles M, Saunders D, Smith N. Novel approaches to combat chemoresistance against glioblastomas. Cancer Drug Resist. 2020;3:686-98.
23. Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir. 2018;58:405-21.
24. De Hauwer C, Camby I, Darro F, et al. Dynamic characterization of glioblastoma cell motility. Biochem Biophys Res Commun. 1997;232:267-72.
25. Hagemann C, Anacker J, Haas S, et al. Comparative expression pattern of matrix-metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res Notes. 2010;3:293.
26. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9:469-79.
27. Bady P, Diserens AC, Castella V, et al. DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro Oncol. 2012;14:701-11.
28. Studer A, de Tribolet N, Diserens AC, et al. Characterization of four human malignant glioma cell lines. Acta Neuropathol. 1985;66:208-17.
29. Guo M, van Vliet M, Zhao J, et al. Identification of functionally distinct and interacting cancer cell subpopulations from glioblastoma with intratumoral genetic heterogeneity. Neurooncol Adv. 2020;2:vdaa061.
30. Al-Mayhani MT, Grenfell R, Narita M, et al. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro Oncol. 2011;13:830-45.
31. Innes JA, Lowe AS, Fonseca R, et al. Phenotyping clonal populations of glioma stem cell reveals a high degree of plasticity in response to changes of microenvironment. Lab Invest. 2022;102:172-84.
32. Rehfeld M, Matschke J, Hagel C, Willenborg K, Glatzel M, Bernreuther C. Differential expression of stem cell markers in proliferating cells in glioma. J Cancer Res Clin Oncol. 2021;147:2969-82.
33. Brown DV, Filiz G, Daniel PM, et al. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS One. 2017;12:e0172791.
34. Mooney KL, Choy W, Sidhu S, et al. The role of CD44 in glioblastoma multiforme. J Clin Neurosci. 2016;34:1-5.
35. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231-51.
36. Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol. 2022;8:1493-501.
37. Kurokawa R, Kurokawa M, Baba A, et al. Major changes in 2021 World Health Organization classification of central nervous system tumors. Radiographics. 2022;42:1474-93.
39. Trifănescu OG, Trifănescu RA, Mitrică R, et al. Upstaging and downstaging in gliomas-clinical implications for the fifth edition of the World Health Organization classification of tumors of the central nervous system. Diagnostics. 2023;13:197.
40. Lu Y, Shao Y. Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival. Cancer Drug Resist. 2022;5:511-33.
41. Listik E, Toma L. Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy. Oncotarget. 2020;11:828-45.
42. Kolliopoulos C, Ali MM, Castillejo-Lopez C, Heldin CH, Heldin P. CD44 depletion in glioblastoma cells suppresses growth and stemness and induces senescence. Cancers. 2022;14:3747.
43. Gudbergsson JM, Christensen E, Kostrikov S, et al. Conventional treatment of glioblastoma reveals persistent CD44+ subpopulations. Mol Neurobiol. 2020;57:3943-55.
44. Tran VM, Wade A, McKinney A, et al. Heparan sulfate glycosaminoglycans in glioblastoma promote tumor invasion. Mol Cancer Res. 2017;15:1623-33.
45. Xiong A, Spyrou A, Forsberg-nilsson K. Involvement of heparan sulfate and heparanase in neural development and pathogenesis of brain tumors. In: Vlodavsky I, Sanderson RD, Ilan N, editors. Heparanase. Cham: Springer International Publishing; 2020. pp. 365-403.
46. Jaime-Ramirez AC, Dmitrieva N, Yoo JY, et al. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide. J Gene Med. 2017;19:e2942.
47. Tsidulko AY, Bezier C, de La Bourdonnaye G, et al. Conventional anti-glioblastoma chemotherapy affects proteoglycan composition of brain extracellular matrix in rat experimental model in vivo. Front Pharmacol. 2018;9:1104.
48. Tsidulko AY, Shevelev OB, Khotskina AS, et al. Chemotherapy-induced degradation of glycosylated components of the brain extracellular matrix promotes glioblastoma relapse development in an animal model. Front Oncol. 2021;11:713139.
49. Aladev SD, Sokolov DK, Strokotova AV, et al. Dexamethasone effects on the expression and content of glycosylated components of mouse brain tissue. Adv Mol Onkol. 2023;10:25-39. (in Russian).
